Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839648 | 0.99 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL1843499 | 0.97 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL1842875 | 0.96 | TLR7 (0.81) | TLR7TLR8 | |
| SCHEMBL1842609 | 0.95 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL1841966 | 0.94 | TLR7 (0.81) | TLR7TLR8 | |
| SCHEMBL1840807 | 0.94 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL12443962 | 0.94 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL1842496 | 0.94 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL1844026 | 0.94 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL1973083 | 0.94 | TLR7 (0.80) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | claimed |
| US-8563717-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2013-10-22 | — | — | US | claimed |
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2011-06-16 | — | — | US | claimed |
| EP-2320905-A1 | NOVEL ADENINE DERIVATIVES | Smithkline Beecham Corporation (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010018134-A1 | NOVEL ADENINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | claimed |
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-8802684-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802684-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563717-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563717-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2320905-A1 | NOVEL ADENINE DERIVATIVES | Smithkline Beecham Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010018134-A1 | NOVEL ADENINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | STING1, IFNG, IFNAR1 | TLR7 12/4885TLR8 212/4885 |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | IFNAR1, STING1, IFNG | TLR7 11/4885TLR8 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.